Skip to main content
. 2022 Oct 18;18(16):6129–6144. doi: 10.7150/ijbs.74951

Figure 1.

Figure 1

Down-regulated BMAL1 in HCC tissues correlated with tumor progression and poor prognosis. (A-B) qRT-PCR and Western blot analyses of BMAL1 in 30 paired tumor and peritumor tissues from HCC patients. Relative tumor to peritumor (T/P) expression ratio of BMAL1 was log2-transformed. qRT-PCR data are presented according to patient serial numbers, while patient serial numbers for Western blot data are rearranged as per expression levels. (C) Correlations between mRNA and protein levels of BMAL1 in 30 paired tissues from HCC patients. (D) Representative IHC-staining images (left), as well as IHC scores (right) for BMAL1 in 217 paired HCC tissues. (E) Representative IHC-staining images (left) and IHC scores (right) for BMAL1 in 36 paired primary and metastatic HCC tissues. *p < 0.05. Scale bar: 100 µm. (F-G) Expressions of BMAL1 in eight HCC cell lines and one normal human hepatocyte (HL-7702) were assessed by qRT-PCR and Western blot assays. (H) Kaplan-Meier assessments of overall (OS) and recurrence-free survival (RFS) outcomes for HCC patients based on BMAL1 expressions (n=217). (I) Bioinformatics analysis of OS and RFS outcomes for HCC patients as per the BMAL1 expression using the Kaplan-Meier plotter survival analysis platform (n=364). *p <0.05.